<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39401361</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>14</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN><JournalIssue CitedMedium="Internet"><Volume>121</Volume><Issue>43</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>22</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>The accomplices: Heparan sulfates and N-glycans foster SARS-CoV-2 spike:ACE2 receptor binding and virus priming.</ArticleTitle><Pagination><StartPage>e2404892121</StartPage><MedlinePgn>e2404892121</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e2404892121</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.2404892121</ELocationID><Abstract><AbstractText>Although it is well established that the SARS-CoV-2 spike glycoprotein binds to the host cell ACE2 receptor to initiate infection, far less is known about the tissue tropism and host cell susceptibility to the virus. Differential expression across different cell types of heparan sulfate (HS) proteoglycans, with variably sulfated glycosaminoglycans (GAGs), and their synergistic interactions with host and viral N-glycans may contribute to tissue tropism and host cell susceptibility. Nevertheless, their contribution remains unclear since HS and N-glycans evade experimental characterization. We, therefore, carried out microsecond-long all-atom molecular dynamics simulations, followed by random acceleration molecular dynamics simulations, of the fully glycosylated spike:ACE2 complex with and without highly sulfated GAG chains bound. By considering the model GAGs as surrogates for the highly sulfated HS expressed in lung cells, we identified key cell entry mechanisms of spike SARS-CoV-2. We find that HS promotes structural and energetic stabilization of the active conformation of the spike receptor-binding domain (RBD) and reorientation of ACE2 toward the N-terminal domain in the same spike subunit as the RBD. Spike and ACE2 N-glycans exert synergistic effects, promoting better packing, strengthening the protein:protein interaction, and prolonging the residence time of the complex. ACE2 and HS binding trigger rearrangement of the S2' functional protease cleavage site through allosteric interdomain communication. These results thus show that HS has a multifaceted role in facilitating SARS-CoV-2 infection, and they provide a mechanistic basis for the development of GAG derivatives with anti-SARS-CoV-2 potential.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Paiardi</LastName><ForeName>Giulia</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0001-6000-0270</Identifier><AffiliationInfo><Affiliation>Molecular and Cellular Modeling Group, Heidelberg Institute for Theoretical Studies (HITS), Heidelberg 69118, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Heidelberg University, Heidelberg 69117, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Zentrum für Molekulare Biologie der Universität Heidelberg (ZMBH), DKFZ-ZMBH Alliance, Heidelberg 69120, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferraz</LastName><ForeName>Matheus</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-6958-3115</Identifier><AffiliationInfo><Affiliation>Molecular and Cellular Modeling Group, Heidelberg Institute for Theoretical Studies (HITS), Heidelberg 69118, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Virology, Aggeu Magalhães Institute, Oswaldo Cruz Foundation, Recife, PE 50740-465, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Fundamental Chemistry, Federal University of Pernambuco, Recife, PE 50740-560, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rusnati</LastName><ForeName>Marco</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-9968-5908</Identifier><AffiliationInfo><Affiliation>Macromolecular Interaction Analysis Unit, Section of Experimental Oncology and Immunology, Department of Molecular and Translational Medicine, Brescia 25123, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wade</LastName><ForeName>Rebecca C</ForeName><Initials>RC</Initials><Identifier Source="ORCID">0000-0001-5951-8670</Identifier><AffiliationInfo><Affiliation>Molecular and Cellular Modeling Group, Heidelberg Institute for Theoretical Studies (HITS), Heidelberg 69118, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Heidelberg University, Heidelberg 69117, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Zentrum für Molekulare Biologie der Universität Heidelberg (ZMBH), DKFZ-ZMBH Alliance, Heidelberg 69120, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Interdisciplinary Center for Scientific Computing (IWR), Heidelberg University, Heidelberg 69120, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>458623378</GrantID><Agency>Deutsche Forschungsgemeinschaft (DFG)</Agency><Country /></Grant><Grant><GrantID>57507871</GrantID><Agency>Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.17.23</RegistryNumber><NameOfSubstance UI="D000085962">Angiotensin-Converting Enzyme 2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000657845">spike protein, SARS-CoV-2</NameOfSubstance></Chemical><Chemical><RegistryNumber>9050-30-0</RegistryNumber><NameOfSubstance UI="D006497">Heparitin Sulfate</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011134">Polysaccharides</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.17.23</RegistryNumber><NameOfSubstance UI="C000705307">ACE2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006025">Glycosaminoglycans</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D064370" MajorTopicYN="Y">Spike Glycoprotein, Coronavirus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000085962" MajorTopicYN="Y">Angiotensin-Converting Enzyme 2</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006497" MajorTopicYN="Y">Heparitin Sulfate</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D056004" MajorTopicYN="Y">Molecular Dynamics Simulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011134" MajorTopicYN="Y">Polysaccharides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011485" MajorTopicYN="Y">Protein Binding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053586" MajorTopicYN="N">Virus Internalization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006025" MajorTopicYN="N">Glycosaminoglycans</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ACE2 receptor</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">glycoprotein interactions</Keyword><Keyword MajorTopicYN="N">heparan sulfate</Keyword><Keyword MajorTopicYN="N">molecular dynamics simulation</Keyword></KeywordList><CoiStatement>Competing interests statement:The authors declare no competing interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>14</Day><Hour>22</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>14</Day><Hour>22</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>14</Day><Hour>15</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>4</Month><Day>14</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39401361</ArticleId><ArticleId IdType="doi">10.1073/pnas.2404892121</ArticleId><ArticleId IdType="pmc">PMC11513917</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Walls A. C., et al. , Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell 181, 281–292.e6 (2020), 10.1016/j.cell.2020.02.058.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.02.058</ArticleId><ArticleId IdType="pmc">PMC7102599</ArticleId><ArticleId IdType="pubmed">32155444</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q., et al. , Structural and functional basis of SARS-CoV-2 entry by using human ACE2. Cell 181, 894–904.e9 (2020), 10.1016/j.cell.2020.03.045.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.03.045</ArticleId><ArticleId IdType="pmc">PMC7144619</ArticleId><ArticleId IdType="pubmed">32275855</ArticleId></ArticleIdList></Reference><Reference><Citation>Lan J., et al. , Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature 581, 215–220 (2020), 10.1038/s41586-020-2180-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2180-5</ArticleId><ArticleId IdType="pubmed">32225176</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan M., et al. , A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV. Science 368, 630–633 (2020), 10.1126/science.abb7269.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abb7269</ArticleId><ArticleId IdType="pmc">PMC7164391</ArticleId><ArticleId IdType="pubmed">32245784</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe Y., Allen J. D., Wrapp D., McLellan J. S., Crispin M., Site-specific glycan analysis of the SARS-CoV-2 spike. Science 369, 330–333 (2020), 10.1126/science.abb9983.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abb9983</ArticleId><ArticleId IdType="pmc">PMC7199903</ArticleId><ArticleId IdType="pubmed">32366695</ArticleId></ArticleIdList></Reference><Reference><Citation>Grant O. C., Montgomery D., Ito K., Woods R. J., Analysis of the SARS-CoV-2 spike protein glycan shield reveals implications for immune recognition. Sci. Rep. 10, 1 (2020), 10.1038/s41598-020-71748-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-71748-7</ArticleId><ArticleId IdType="pmc">PMC7490396</ArticleId><ArticleId IdType="pubmed">32929138</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y., Butler M., Quantitative profiling of N-glycosylation of SARS-CoV-2 spike protein variants. Glycobiology 33, 188–202 (2023), 10.1093/glycob/cwad007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/glycob/cwad007</ArticleId><ArticleId IdType="pmc">PMC10114651</ArticleId><ArticleId IdType="pubmed">36723867</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao P., et al. , Virus-receptor interactions of glycosylated SARS-CoV-2 spike and human ACE2 receptor. Cell Host Microbe 28, 586–601.e6 (2020), 10.1016/j.chom.2020.08.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2020.08.004</ArticleId><ArticleId IdType="pmc">PMC7443692</ArticleId><ArticleId IdType="pubmed">32841605</ArticleId></ArticleIdList></Reference><Reference><Citation>Casalino L., et al. , Beyond shielding: The roles of glycans in the SARS-CoV-2 spike protein. ACS Cent. Sci. 6, 1722–1734 (2020), 10.1021/acscentsci.0c01056.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acscentsci.0c01056</ArticleId><ArticleId IdType="pmc">PMC7523240</ArticleId><ArticleId IdType="pubmed">33140034</ArticleId></ArticleIdList></Reference><Reference><Citation>Sztain T., et al. , A glycan gate controls opening of the SARS-CoV-2 spike protein. Nat. Chem. 13, 963–968 (2021), 10.1038/s41557-021-00758-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41557-021-00758-3</ArticleId><ArticleId IdType="pmc">PMC8488004</ArticleId><ArticleId IdType="pubmed">34413500</ArticleId></ArticleIdList></Reference><Reference><Citation>Harbison A. M., et al. , Fine-tuning the spike: Role of the nature and topology of the glycan shield in the structure and dynamics of the SARS-CoV-2 S. Chem. Sci. 13, 386–395 (2022), 10.1039/d1sc04832e.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/d1sc04832e</ArticleId><ArticleId IdType="pmc">PMC8729800</ArticleId><ArticleId IdType="pubmed">35126971</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Q., et al. , Inhibition of SARS-CoV-2 viral entry upon blocking N- and O-glycan elaboration. Elife 9, e61552 (2020), 10.7554/eLife.61552.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.61552</ArticleId><ArticleId IdType="pmc">PMC7685702</ArticleId><ArticleId IdType="pubmed">33103998</ArticleId></ArticleIdList></Reference><Reference><Citation>Nangarlia A., et al. , Irreversible inactivation of SARS-CoV-2 by lectin engagement with two glycan clusters on the spike protein. Biochemistry 62, 2115–2127 (2023), 10.1021/acs.biochem.3c00109.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.biochem.3c00109</ArticleId><ArticleId IdType="pmc">PMC10663058</ArticleId><ArticleId IdType="pubmed">37341186</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori T., et al. , Elucidation of interactions regulating conformational stability and dynamics of SARS-CoV-2 S-protein. Biophys. J. 120, 1060–1071 (2021), 10.1016/j.bpj.2021.01.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bpj.2021.01.012</ArticleId><ArticleId IdType="pmc">PMC7825899</ArticleId><ArticleId IdType="pubmed">33484712</ArticleId></ArticleIdList></Reference><Reference><Citation>Newby M. L., et al. , Variations within the glycan shield of SARS-CoV-2 impact viral spike dynamics. J. Mol. Biol. 435, 167928 (2023), 10.1016/j.jmb.2022.167928.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmb.2022.167928</ArticleId><ArticleId IdType="pmc">PMC9769069</ArticleId><ArticleId IdType="pubmed">36565991</ArticleId></ArticleIdList></Reference><Reference><Citation>Turoňová B., et al. , In situ structural analysis of SARS-CoV-2 spike reveals flexibility mediated by three hinges. Science 370, 203–208 (2020), 10.1126/science.abd5223.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abd5223</ArticleId><ArticleId IdType="pmc">PMC7665311</ArticleId><ArticleId IdType="pubmed">32817270</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann M., et al. , SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181, 271–280.e8 (2020), 10.1016/j.cell.2020.02.052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.02.052</ArticleId><ArticleId IdType="pmc">PMC7102627</ArticleId><ArticleId IdType="pubmed">32142651</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang J., et al. , Molecular interaction and inhibition of SARS-CoV-2 binding to the ACE2 receptor. Nat. Commun. 11, 4541 (2020), 10.1038/s41467-020-18319-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-18319-6</ArticleId><ArticleId IdType="pmc">PMC7486399</ArticleId><ArticleId IdType="pubmed">32917884</ArticleId></ArticleIdList></Reference><Reference><Citation>Shin Y. H., et al. , Inhibition of ACE2-spike interaction by an ACE2 binder suppresses SARS-CoV-2 entry. Angew. Chem. Int. Ed. 61, e202115695 (2022), 10.1002/anie.202115695.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/anie.202115695</ArticleId><ArticleId IdType="pmc">PMC9011661</ArticleId><ArticleId IdType="pubmed">35043545</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu S., et al. , SARS-CoV-2 spike engagement of ACE2 primes S2’ site cleavage and fusion initiation. Proc. Natl. Acad. Sci. U. S. A. 119, e2111199119 (2022), 10.1073/pnas.2111199119.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2111199119</ArticleId><ArticleId IdType="pmc">PMC8740742</ArticleId><ArticleId IdType="pubmed">34930824</ArticleId></ArticleIdList></Reference><Reference><Citation>Vankadari N., et al. , Structure of human TMPRSS2 in complex with SARS-CoV-2 spike glycoprotein and implications for potential therapeutics. J. Phys. Chem. Lett. 13, 5324–5333 (2022), 10.1021/acs.jpclett.2c00967.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jpclett.2c00967</ArticleId><ArticleId IdType="pubmed">35675654</ArticleId></ArticleIdList></Reference><Reference><Citation>Essalmani R., et al. , Distinctive roles of furin and TMPRSS2 in SARS-CoV-2 infectivity. J. Virol. 96, e0012822 (2022), 10.1128/jvi.00128-22.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.00128-22</ArticleId><ArticleId IdType="pmc">PMC9044946</ArticleId><ArticleId IdType="pubmed">35343766</ArticleId></ArticleIdList></Reference><Reference><Citation>Dodero-Rojas E., Onuchic J. N., Whitford P. C., Sterically confined rearrangements of SARS-CoV-2 spike protein control cell invasion. Elife 10, e70362 (2021), 10.7554/eLife.70362.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.70362</ArticleId><ArticleId IdType="pmc">PMC8456623</ArticleId><ArticleId IdType="pubmed">34463614</ArticleId></ArticleIdList></Reference><Reference><Citation>Clausen T. M., et al. , SARS-CoV-2 infection depends on cellular heparan sulfate and ACE2. Cell 183, 1043–1057.e15 (2020), 10.1016/j.cell.2020.09.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.09.033</ArticleId><ArticleId IdType="pmc">PMC7489987</ArticleId><ArticleId IdType="pubmed">32970989</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim S. Y., et al. , Characterization of heparin and severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) spike glycoprotein binding interactions. Antiviral Res. 181, 104873 (2020), 10.1016/j.antiviral.2020.104873.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2020.104873</ArticleId><ArticleId IdType="pmc">PMC7347485</ArticleId><ArticleId IdType="pubmed">32653452</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu L., et al. , Heparan sulfate proteoglycans as attachment factor for SARS-CoV-2. ACS Cent. Sci. 7, 1009–1018 (2021), 10.1021/acscentsci.1c00010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acscentsci.1c00010</ArticleId><ArticleId IdType="pmc">PMC8227597</ArticleId><ArticleId IdType="pubmed">34235261</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun L., et al. , Well-defined heparin mimetics can inhibit binding of the trimeric spike of SARS-CoV-2 in a length-dependent manner. JACS Au 3, 1185–1195 (2023), 10.1021/jacsau.3c00042.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jacsau.3c00042</ArticleId><ArticleId IdType="pmc">PMC10089289</ArticleId><ArticleId IdType="pubmed">37101566</ArticleId></ArticleIdList></Reference><Reference><Citation>Yue J., et al. , Heparan sulfate facilitates spike protein-mediated SARS-CoV-2 host cell invasion and contributes to increased infection of SARS-CoV-2 G614 mutant and in lung cancer. Front. Mol. Biosci. 8, 649575 (2021), 10.3389/fmolb.2021.649575.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmolb.2021.649575</ArticleId><ArticleId IdType="pmc">PMC8231436</ArticleId><ArticleId IdType="pubmed">34179075</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Q., et al. , Heparan sulfate assists SARS-CoV-2 in cell entry and can be targeted by approved drugs in vitro. Cell Discov. 6, 80 (2020), 10.1038/s41421-020-00222-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41421-020-00222-5</ArticleId><ArticleId IdType="pmc">PMC7610239</ArticleId><ArticleId IdType="pubmed">33298900</ArticleId></ArticleIdList></Reference><Reference><Citation>Kearns F. L., et al. , Spike-heparan sulfate interactions in SARS-CoV-2 infection. Curr. Opin. Struct. Biol. 76, 102439 (2022), 10.1016/j.sbi.2022.102439.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.sbi.2022.102439</ArticleId><ArticleId IdType="pmc">PMC9257145</ArticleId><ArticleId IdType="pubmed">35926454</ArticleId></ArticleIdList></Reference><Reference><Citation>Hogwood J., Mulloy B., Lever R., Gray E., Page C. P., Pharmacology of heparin and related drugs: An update. Pharmacol. Rev. 75, 328–379 (2023), 10.1124/pharmrev.122.000684.</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/pharmrev.122.000684</ArticleId><ArticleId IdType="pubmed">36792365</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim S. H., et al. , GlycoGrip: Cell surface-inspired universal sensor for betacoronaviruses. ACS Cent. Sci. 8, 22–42 (2022), 10.1021/acscentsci.1c01080.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acscentsci.1c01080</ArticleId><ArticleId IdType="pmc">PMC8796303</ArticleId><ArticleId IdType="pubmed">35106370</ArticleId></ArticleIdList></Reference><Reference><Citation>Tree J. A., et al. , Unfractionated heparin inhibits live wild type SARS-CoV-2 cell infectivity at therapeutically relevant concentrations. Br. J. Pharmacol. 178, 626–635 (2021), 10.1111/bph.15304.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bph.15304</ArticleId><ArticleId IdType="pmc">PMC9328389</ArticleId><ArticleId IdType="pubmed">33125711</ArticleId></ArticleIdList></Reference><Reference><Citation>Mycroft-West C. J., et al. , Heparin inhibits cellular invasion by SARS-CoV-2: Structural dependence of the interaction of the spike S1 receptor-binding domain with heparin. Thromb. Haemost. 120, 1700–1715 (2020), 10.1055/s-0040-1721319.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0040-1721319</ArticleId><ArticleId IdType="pmc">PMC7869224</ArticleId><ArticleId IdType="pubmed">33368089</ArticleId></ArticleIdList></Reference><Reference><Citation>Paiardi G., et al. , The binding of heparin to spike glycoprotein inhibits SARS-CoV-2 infection by three mechanisms. J. Biol. Chem. 298, 101507 (2022), 10.1016/j.jbc.2021.101507.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbc.2021.101507</ArticleId><ArticleId IdType="pmc">PMC8683219</ArticleId><ArticleId IdType="pubmed">34929169</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim S. H., et al. , SARS-CoV-2 evolved variants optimize binding to cellular glycocalyx. Cell Rep. Phys. Sci. 4, 101346 (2023), 10.1016/j.xcrp.2023.101346.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xcrp.2023.101346</ArticleId><ArticleId IdType="pmc">PMC10080732</ArticleId><ArticleId IdType="pubmed">37077408</ArticleId></ArticleIdList></Reference><Reference><Citation>Cecon E., et al. , SARS-COV-2 spike binding to ACE2 in living cells monitored by TR-FRET. Cell Chem. Biol. 29, 74–83.e4 (2022), 10.1016/j.chembiol.2021.06.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chembiol.2021.06.008</ArticleId><ArticleId IdType="pmc">PMC8249686</ArticleId><ArticleId IdType="pubmed">34246414</ArticleId></ArticleIdList></Reference><Reference><Citation>Petitjean S. J. L., et al. , Heparin-induced allosteric changes in SARS-CoV-2 spike protein facilitate ACE2 binding and viral entry. Nano Lett. 23, 11678–11684 (2023), 10.1021/acs.nanolett.3c03550.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.nanolett.3c03550</ArticleId><ArticleId IdType="pubmed">38055954</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Y., Du Y., Kaltashov I. A., The utility of native MS for understanding the mechanism of action of repurposed therapeutics in COVID-19: Heparin as a disruptor of the SARS-CoV-2 interaction with its host cell receptor. Anal. Chem. 92, 10930–10934 (2020), 10.1021/acs.analchem.0c02449.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.analchem.0c02449</ArticleId><ArticleId IdType="pmc">PMC7384394</ArticleId><ArticleId IdType="pubmed">32678978</ArticleId></ArticleIdList></Reference><Reference><Citation>Kollman P. A., et al. , Calculating structures and free energies of complex molecules: Combining molecular mechanics and continuum models. Acc. Chem. Res. 33, 889–897 (2000), 10.1021/ar000033j.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/ar000033j</ArticleId><ArticleId IdType="pubmed">11123888</ArticleId></ArticleIdList></Reference><Reference><Citation>Genheden S., Ryde U., The MM/PBSA and MM/GBSA methods to estimate ligand-binding affinities. Expert Opin. Drug Discov. 10, 449–461 (2015), 10.1517/17460441.2015.1032936.</Citation><ArticleIdList><ArticleId IdType="doi">10.1517/17460441.2015.1032936</ArticleId><ArticleId IdType="pmc">PMC4487606</ArticleId><ArticleId IdType="pubmed">25835573</ArticleId></ArticleIdList></Reference><Reference><Citation>Shang J., et al. , Structural basis of receptor recognition by SARS-CoV-2. Nature 581, 221–224 (2020), 10.1038/s41586-020-2179-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2179-y</ArticleId><ArticleId IdType="pmc">PMC7328981</ArticleId><ArticleId IdType="pubmed">32225175</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams J. K., et al. , Molecular dynamics analysis of a flexible loop at the binding interface of the SARS-CoV-2 spike protein receptor-binding domain. Proteins 90, 1044–1053 (2022), 10.1002/prot.26208.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/prot.26208</ArticleId><ArticleId IdType="pmc">PMC8441656</ArticleId><ArticleId IdType="pubmed">34375467</ArticleId></ArticleIdList></Reference><Reference><Citation>Spinello A., Saltalamacchia A., Magistrato A., Is the rigidity of SARS-CoV-2 spike receptor-binding motif the hallmark for its enhanced infectivity? Insights from all-atom simulations J. Phys. Chem. Lett. 11, 4785–4790 (2020), 10.1021/acs.jpclett.0c01148.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jpclett.0c01148</ArticleId><ArticleId IdType="pubmed">32463239</ArticleId></ArticleIdList></Reference><Reference><Citation>Verkhivker G., Alshahrani M., Gupta G., Xiao S., Tao P., Probing conformational landscapes of binding and allostery in the SARS-CoV-2 omicron variant complexes using microsecond atomistic simulations and perturbation-based profiling approaches: Hidden role of omicron mutations as modulators of allosteric signaling and epistatic relationships. Phys. Chem. Chem. Phys. 25, 21245–21266 (2023), 10.1039/D3CP02042H.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/D3CP02042H</ArticleId><ArticleId IdType="pmc">PMC10536792</ArticleId><ArticleId IdType="pubmed">37548589</ArticleId></ArticleIdList></Reference><Reference><Citation>Qing E., et al. , Dynamics of SARS-CoV-2 spike proteins in cell entry: Control elements in the amino-terminal domains. mBio 12, e0159021 (2021), 10.1128/mBio.01590-21.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mBio.01590-21</ArticleId><ArticleId IdType="pmc">PMC8406164</ArticleId><ArticleId IdType="pubmed">34340537</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu C., et al. , Conformational dynamics of SARS-CoV-2 trimeric spike glycoprotein in complex with receptor ACE2 revealed by cryo-EM. Sci. Adv. 7, eabe5575 (2021), 10.1126/sciadv.abe5575.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciadv.abe5575</ArticleId><ArticleId IdType="pmc">PMC7775788</ArticleId><ArticleId IdType="pubmed">33277323</ArticleId></ArticleIdList></Reference><Reference><Citation>Qing E., et al. , Inter-domain communication in SARS-CoV-2 spike proteins controls protease-triggered cell entry. Cell Rep. 39, 110786 (2022), 10.1016/j.celrep.2022.110786.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2022.110786</ArticleId><ArticleId IdType="pmc">PMC9015963</ArticleId><ArticleId IdType="pubmed">35477024</ArticleId></ArticleIdList></Reference><Reference><Citation>Meng B., et al. , SARS-CoV-2 spike N-terminal domain modulates TMPRSS2-dependent viral entry and fusogenicity. Cell Rep. 40, 111220 (2022), 10.1016/j.celrep.2022.111220.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2022.111220</ArticleId><ArticleId IdType="pmc">PMC9346021</ArticleId><ArticleId IdType="pubmed">35963244</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang H.-C., et al. , Targeting conserved N-glycosylation blocks SARS-CoV-2 variant infection in vitro. EBioMedicine 74, 103712. (2021), 10.1016/j.ebiom.2021.103712.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2021.103712</ArticleId><ArticleId IdType="pmc">PMC8613501</ArticleId><ArticleId IdType="pubmed">34839261</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Q., et al. , The impact of mutations in SARS-CoV-2 spike on viral infectivity and antigenicity. Cell 182, 1284–1294.e9 (2020), 10.1016/j.cell.2020.07.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.07.012</ArticleId><ArticleId IdType="pmc">PMC7366990</ArticleId><ArticleId IdType="pubmed">32730807</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehdipour A. R., Hummer G., Dual nature of human ACE2 glycosylation in binding to SARS-CoV-2 spike. Proc. Natl. Acad. Sci. U.S.A. 118, e2100425118 (2021), 10.1073/pnas.2100425118.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2100425118</ArticleId><ArticleId IdType="pmc">PMC8126795</ArticleId><ArticleId IdType="pubmed">33903171</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsu Y. P., et al. , Structural remodeling of SARS-CoV-2 spike protein glycans reveals the regulatory roles in receptor-binding affinity. Glycobiology 33, 126–137 (2023), 10.1093/glycob/cwac077.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/glycob/cwac077</ArticleId><ArticleId IdType="pmc">PMC9990995</ArticleId><ArticleId IdType="pubmed">36370046</ArticleId></ArticleIdList></Reference><Reference><Citation>Kokh D. B., et al. , Estimation of drug-target residence times by τ-random acceleration molecular dynamics simulations. J. Chem. Theory Comput. 14, 3859–3869 (2018), 10.1021/acs.jctc.8b00230.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jctc.8b00230</ArticleId><ArticleId IdType="pubmed">29768913</ArticleId></ArticleIdList></Reference><Reference><Citation>Kokh D. B., et al. , A workflow for exploring ligand dissociation from a macromolecule: Efficient random acceleration molecular dynamics simulation and interaction fingerprint analysis of ligand trajectories. J. Chem. Phys. 153, 125102 (2020), 10.1063/5.0019088.</Citation><ArticleIdList><ArticleId IdType="doi">10.1063/5.0019088</ArticleId><ArticleId IdType="pubmed">33003755</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu R., et al. , Force-tuned avidity of spike variant-ACE2 interactions viewed on the single-molecule level. Nat. Commun. 13, 7926 (2022), 10.1038/s41467-022-35641-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-35641-3</ArticleId><ArticleId IdType="pmc">PMC9789309</ArticleId><ArticleId IdType="pubmed">36566234</ArticleId></ArticleIdList></Reference><Reference><Citation>Costescu B. I., Gräter F., Time-resolved force distribution analysis. BMC Biophys. 6, 5 (2013), 10.1186/2046-1682-6-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/2046-1682-6-5</ArticleId><ArticleId IdType="pmc">PMC3669045</ArticleId><ArticleId IdType="pubmed">24499624</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng M. H., et al. , Superantigenic character of an insert unique to SARS-CoV-2 spike supported by skewed TCR repertoire in patients with hyperinflammation. Proc. Natl. Acad. Sci. U. S. A. 117, 25254–25262 (2020), 10.1073/pnas.2010722117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2010722117</ArticleId><ArticleId IdType="pmc">PMC7568239</ArticleId><ArticleId IdType="pubmed">32989130</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsieh C.-L., et al. , Structure-based design of prefusion-stabilized SARS-CoV-2 spikes. Science 369, 1501–1505 (2020), 10.1126/science.abd0826.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abd0826</ArticleId><ArticleId IdType="pmc">PMC7402631</ArticleId><ArticleId IdType="pubmed">32703906</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu M., et al. , SARS-CoV-2 prefusion spike protein stabilized by six rather than two prolines is more potent for inducing antibodies that neutralize viral variants of concern. Proc. Natl. Acad. Sci. U. S. A. 119, e2110105119 (2022), 10.1073/pnas.2110105119.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2110105119</ArticleId><ArticleId IdType="pmc">PMC9436349</ArticleId><ArticleId IdType="pubmed">35994646</ArticleId></ArticleIdList></Reference><Reference><Citation>Low J. S., et al. , ACE2-binding exposes the SARS-CoV-2 fusion peptide to broadly neutralizing coronavirus antibodies. Science 377, 735–742 (2022), 10.1126/science.abq2679.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abq2679</ArticleId><ArticleId IdType="pmc">PMC9348755</ArticleId><ArticleId IdType="pubmed">35857703</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Q., et al. , Role for N-glycans and calnexin-calreticulin chaperones in SARS-CoV-2 spike maturation and viral infectivity. Sci. Adv. 8, eabq8678 (2022), 10.1126/sciadv.abq8678.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciadv.abq8678</ArticleId><ArticleId IdType="pmc">PMC9506717</ArticleId><ArticleId IdType="pubmed">36149962</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng L., et al. , SARS-CoV-2 spike protein receptor-binding domain N-glycans facilitate viral internalization in respiratory epithelial cells. Biochem. Biophys. Res. Commun. 579, 69–75 (2021), 10.1016/j.bbrc.2021.09.053.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2021.09.053</ArticleId><ArticleId IdType="pmc">PMC8459579</ArticleId><ArticleId IdType="pubmed">34592572</ArticleId></ArticleIdList></Reference><Reference><Citation>Capraz T., et al. , Structure-guided glyco-engineering of ACE2 for improved potency as soluble SARS-CoV-2 decoy receptor. Elife 10, e73641 (2021), 10.7554/eLife.73641.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.73641</ArticleId><ArticleId IdType="pmc">PMC8730730</ArticleId><ArticleId IdType="pubmed">34927585</ArticleId></ArticleIdList></Reference><Reference><Citation>Barros E. P., et al. , The flexibility of ACE2 in the context of SARS-CoV-2 infection. Biophys. J. 120, 1072–1084 (2021), 10.1016/j.bpj.2020.10.036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bpj.2020.10.036</ArticleId><ArticleId IdType="pmc">PMC7661960</ArticleId><ArticleId IdType="pubmed">33189680</ArticleId></ArticleIdList></Reference><Reference><Citation>Conca D. V., et al. , Variant-specific interactions at the plasma membrane: Heparan sulfate’s impact on SARS-CoV-2 binding kinetics. bioRxiv [Preprint] (2024). https://www.biorxiv.org/content/10.1101/2024.01.10.574981v1 (Accessed 25 September 2024).</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2024.01.10.574981v1</ArticleId></ArticleIdList></Reference><Reference><Citation>Bugatti A., et al. , Heparin and heparan sulfate proteoglycans promote HIV-1 p17 matrix protein oligomerization: Computational, biochemical and biological implications. Sci. Rep. 9, 15768 (2019), 10.1038/s41598-019-52201-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-019-52201-w</ArticleId><ArticleId IdType="pmc">PMC6823450</ArticleId><ArticleId IdType="pubmed">31673058</ArticleId></ArticleIdList></Reference><Reference><Citation>Asor R., et al. , Cooperativity and induced oligomerisation control the interaction of SARS-CoV-2 with its cellular receptor and patient-derived antibodies. bioRxiv [Preprint] (2023). https://www.biorxiv.org/content/10.1101/2023.09.14.557399v1 (Accessed 25 September 2024).</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2023.09.14.557399v1</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H., Robertson A. D., Jensen J. H., Very fast empirical prediction and rationalization of protein pKa values. Proteins 61, 704–721 (2005), 10.1002/prot.20660.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/prot.20660</ArticleId><ArticleId IdType="pubmed">16231289</ArticleId></ArticleIdList></Reference><Reference><Citation>Dolinsky T. J., Nielsen J. E., McCammon J. A., Baker N. A., PDB2PQR: An automated pipeline for the setup of Poisson-Boltzmann electrostatics calculations. Nucleic Acids Res. 32, W665–W667 (2004), 10.1093/nar/gkh381.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkh381</ArticleId><ArticleId IdType="pmc">PMC441519</ArticleId><ArticleId IdType="pubmed">15215472</ArticleId></ArticleIdList></Reference><Reference><Citation>Paiardi G., Ferraz M., Rusnati M., Wade R. C., SARS-CoV2 spike glycoprotein homotrimeric head- in an open conformation with ACE2 bound (1µs). BioExcel-cv19. https://bioexcel-cv19.bsc.es/#/id/MCV1901746. Deposited 6 February 2024.</Citation></Reference><Reference><Citation>Paiardi G., Ferraz M., Rusnati M., Wade R. C., SARS-CoV2 spike glycoprotein homotrimeric head- in an open conformation with ACE2 and three 31-monosaccharides heparin chain bound (1µs). BioExcel-cv19. https://bioexcel-cv19.bsc.es/#/id/MCV1901747. Deposited 6 February 2024.</Citation></Reference><Reference><Citation>Paiardi G., Ferraz M., Rusnati M., Wade R. C., The accomplices: Heparan sulfates and N-glycans foster SARS-CoV-2 spike:ACE2 receptor binding and virus priming. Zenodo. https://zenodo.org/records/10617411. Deposited 5 February 2024.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11513917</ArticleId><ArticleId IdType="pubmed">39401361</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>